Ariosa Diagnostics inks deal with LabCorp for prenatal test

Ariosa Diagnostics has signed a deal with LabCorp to bring the startup's Down syndrome-related prenatal blood test to labs around the country. The California company launched the Harmony Prenatal Test earlier this year, and it's designed to detect the genetic condition Trisomy 21, which has been linked to Down syndrome, Forbes reports. The deal with LabCorp will get Ariosa's noninvasive screening into more than 1,000 labs around the U.S., and, at $795 a pop, the test is cheaper than rival Sequenom's $1,900 MaterniT21. Report

Suggested Articles

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

Drug-pricing watchdog ICER has partnered with medical data firm Aetion to help analyze the real-world performance of different treatments.